Enhanced Launches Personalized Performance Platform, Eyes Peptide Market Expansion
Event summary
- Enhanced launched its personalized performance medicine and supplement platform on March 18, 2026, with initial offerings including proprietary Stronger & Longer supplement lines and hormone replacement therapies.
- The company plans to expand its product catalog to include peptides, capitalizing on potential regulatory shifts allowing licensed pharmacies to compound 14 previously restricted peptide compounds.
- Enhanced is developing female-specific performance protocols in partnership with Dama Health co-founders Elena Rueda Carrasco and Dr. Paulina Cecula.
- The company is sponsoring an IRB-approved clinical trial with 40 elite athletes ahead of its inaugural Enhanced Games event on May 24, 2026.
The big picture
Enhanced is positioning itself at the intersection of performance medicine and personalized healthcare, leveraging its athlete data and regulatory opportunities to capture market share. The company's strategic focus on peptides and female-specific protocols addresses significant gaps in the current performance medicine landscape. With the global peptide therapeutics market projected to reach $87 billion by 2035, Enhanced's timing and product strategy could prove highly lucrative if regulatory shifts materialize as anticipated.
What we're watching
- Regulatory Tailwinds
- The pace at which the FDA reclassifies peptide compounds will determine Enhanced's ability to capitalize on the $52 billion peptide therapeutics market.
- Competitive Differentiation
- Whether Enhanced can sustain its competitive advantage through proprietary data from its athlete clinical trials and personalized product offerings.
- Market Expansion
- How the company's female-specific performance protocols will perform in a historically underserved market segment.
Related topics